Edelman, E. Jennifer
Moore, Brent A.
Calabrese, Sarah K.
Berkenblit, Gail
Cunningham, Chinazo
Patel, Viraj
Phillips, Karran
Tetrault, Jeanette M.
Shah, Minesh
Fiellin, David A.
Blackstock, Oni
Funding for this research was provided by:
CTSA (UL1 TR000142)
National Institute on Drug Abuse (K12DA033312-03)
National Institute on Drug Abuse (R01 DA034678)
National Institute of Mental Health (K01-MH103080, K23MH102129-03)
Article History
First Online: 28 November 2016
Compliance with Ethical Standards
:
: Dr. Fiellin has received honoraria from Pinney Associates for serving on an external advisory board monitoring the diversion and abuse of buprenorphine. The authors have no other conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was reviewed and considered exempt by both Yale University and Albert Einstein College of Medicine’s Humans Investigation Committees.
: Informed consent was obtained from all individual participants.